Treatment of liver cirrhosis and its complications

Details Treatment of liver cirrhosis and its complications Treatment of liver cirrhosis and its complications

2011-01-11

2011-01-11

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S141100, C424S142100, C424S145100

Reexamination Certificate

active

07867490

ABSTRACT:
The present invention relates to the field of liver diseases, more particularly to the field of portal hypertension and liver cirrhosis. The invention relates to the use of molecules which can inhibit the binding of placental growth factor (PIGF) to its receptor (VEGFR-1), such as monoclonal antibodies, for the manufacture of a medicament to treat liver cirrhosis, portal hypertension and its complications.

REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5851999 (1998-12-01), Ullrich et al.
patent: 5919899 (1999-07-01), Persico et al.
patent: 6369204 (2002-04-01), Kim et al.
patent: 2002/0009750 (2002-01-01), Rockwell et al.
patent: 2003/0180286 (2003-09-01), Carmeliet et al.
patent: 2001/086982 (2001-04-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 97/15330 (1997-05-01), None
patent: WO 98/13071 (1998-04-01), None
patent: WO 99/24056 (1999-05-01), None
patent: WO 99/60846 (1999-12-01), None
patent: WO 01/85796 (2001-11-01), None
patent: WO 01/85796 (2001-11-01), None
patent: WO 03/000183 (2003-01-01), None
patent: WO 03/103581 (2003-12-01), None
Webster's II New Riverside University Dictionary, p. 933, 1994.
Ahmed, A., et al., “Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen—a review,” Placenta, (2000), vol. 21 Suppl A, S16-S24.
Bais, C., et al., “PIGF blockade does not inhibit angiogenesis during primary tumor growth,” Cell, (2010), pp. 166-177, vol. 141.
Barillari, G., et al. “The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis,” Am. J. Pathol., (1998), pp. 1161-1166, vol. 152.
Bernatchez, P.N., et al., Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent, J. Biol. Chem., (1999), pp. 31047-31054, vol. 274.
Bicknell, R., et al. “1.Introduction / 2. In vivo models of angiogenesis. In Tumour Angiogenesis,” (1997), pp. 1-18, (Oxford University Press).
Bottomley, M.J., et al., “Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid,” Clin. Exp. Immunol., (2000), pp. 182-188, vol. 119.
Boulton, M., et al., “Placental growth factor localisation in diabetic retinas and preretinal membranes,” Invest Ophthalmol. Vis. Sci., (1997), vol. 38, S965.
Brenchley, P.E., Angiogenesis in inflammatory joint disease: a target for therapeutic intervention, Clin. Exp. Immunol., (2000), pp. 426-429, vol. 121.
Carmeliet, P., “Basic Concepts of (Myocardial) Angiogenesis: Role of Vascular Endothelial Growth Factor and Angiopoietin,” Curr. Intern. Cardiol. Rep. 1, (1999), pp. 322-335.
Carmeliet, P. “Gene targeting and gene transfer to unravel the molecular basis of the formation and disorders of blood vessels,” Verh K Acad Geneesk BeIg, (2000), pp. 31-68, vol. 62.
Carmeliet, P. et al., “Molecular analysis of blood vessel formation and disease,” Am. J. Physiol, (1997), pp. H2091-H2104, vol. 273.
Carmeliet, P. et al., “Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development,” Curr. Top. Microbiol. Immunol., (1999), pp. 133-158, vol. 237.
Carmeliet, P. et al., “Transgenic mouse models in angiogenesis and cardiovascular disease,” J. Pathol., (2000), pp. 387-405, vol. 190.
Carmeliet, P., “Mechanisms of angiogenesis and arteriogenesis,” Nat. Med., (2000), pp. 389-395, vol. 6.
Carmeliet, P., “Molecular mechanisms of normal and pathologic angiogenesis: insights and therapeutic concepts from transgenic cells,” Journal of Vascular Research, (2000), p. 79. vol. 37.
Carmeliet, P., et al., “Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions,” Nat. Med., (2001), pp. 575-583, vol. 7.
Chen,Y. et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J. Mol. Biol., (1999), pp. 865-881, vol. 293.
Christinger, H.W. et al., “The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1,” J. Biol. Chem., (2004), pp. 10382-10388, vol. 279.
Colucciello, M., “Diabetic retinopathy. Control of systemic factors preserves vision,” Postgrad. Med., (2004), pp. 57-64, vol. 116.
Declerck, P.J., et al., “Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice,” J. Biol. Chem., (1995), pp. 8397-8400, vol. 270.
Dias, S., et al., “Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias,” Proc. Natl. Acad. Sci. U. S., (2001), pp. 10857-10862, vol. A 98.
Donnini, S., et al., Expression and localization of placenta growth factor and PIGF receptors in human meningiomas, J. Pathol., (1999), pp. 66-71, vol. 189.
Fidler, I.J., et al., “Biology of Cancer:Angiogenesis. In Cancer. Principles & Practice of Oncology, Lippincott Williams & Wilkins),” (2000), pp. 137-147.
Fischer, C., et al., “Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels,” Cell, (2007), pp. 463-475, vol. 131.
Fischer, C., et al., “Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels,” Cell, (2007), pp. 463-475, vol. 131—Supplementary Data.
Folkman, J., “Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis, ” N. Engl. J. Med., (1995), pp. 1757-1763, vol. 333.
Griffioen, A.W., et al., “Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation,” Pharmacol. Rev., (2000), pp. 237-268, vol. 52.
Guidi, A.J., et al., Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma, Cancer, (1996), pp. 454-460, vol. 78.
Gura, T., “Systems for identifying new drugs are often faulty,” Science, (1997), pp. 1041-1042, vol. 278.
Johnstone, A., et al., “Production of antibodies. In Immunochemistry in practice,” Blackwell Scientific Publications, (1987), p. 30.
Hazelton, D.A., et al., “Vascular endothelial growth factor in ovarian cancer,” Curr. Oncol. Rep. 1, (1999), pp. 59-63.
Hansma et al. “Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer,” Annals of Oncology 16, 1695-1701 (2005).
Holm, P., et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Mol. Immunol., (2007), pp. 1075-1084, vol. 44.
Inoue, H., et al., “Mechanism of mustard oil-induced skin inflammation in mice,” Eur. J. Pharmacol., (1997), pp. 231-240, vol. 333.
Iyer, S., et al., The crystal structure of human placenta growth factor-1 (PIGF-1), an angiogenic protein, at 2.0 A resolution, J. Biol. Chem., (2001), pp. 12153-12161, vol. 276.
Jain, R.K., et al., “alphaPIGF: a new kid on the antiangiogenesis block,” Cell, (2007), pp. 443-445, vol. 131.
Johnstone, A., et al., “Production of antibodies. In Immunochemistry in practice, Blackwell Scientific Publications,” (1987), p. 30.
Kanno, S., et al., Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells, Onc

Affiliated with

Also associated with

Rating

Treatment of liver cirrhosis and its complications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of liver cirrhosis and its complications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of liver cirrhosis and its complications will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2636879